Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	3,738	4,932	10,774	13,274
General and administrative	2,147	2,172	6,715	6,629
Depreciation and amortization	21	31	81	95
Total operating expenses	5,906	7,135	17,570	19,998
Loss from operations	(5,906)	(7,135)	(17,570)	(19,998)
Other income (loss):
Gain from change in fair value of warrant liability	1,591	0	1,031	0
Transaction costs allocated to warrant liabilities	(530)	0	(1,737)	0
Loss on issuance of warrant liabilities	(20,609)	0	(30,962)	0
Other income, net	16	9	30	31
Interest income, net	39	102	96	503
Net loss	$ (25,399)	$ (7,024)	$ (49,112)	$ (19,464)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.68)	$ (1.89)	$ (2.36)	$ (6.69)
Weighted average common shares outstanding, basic and diluted (in shares)	37,304,455	3,714,278	20,827,296	2,910,842
Net loss	$ (25,399)	$ (7,024)	$ (49,112)	$ (19,464)
Other comprehensive income (loss):
Foreign currency translation	(6)	14	(3)	13
Comprehensive loss	$ (25,405)	$ (7,010)	$ (49,115)	$ (19,451)